Home  ›  Mexicans Who Invented the Vaccin Agains Ebola?

Mexicans Who Invented the Vaccin Agains Ebola?

Written By Sunday, 24 April 2022 Add Comment Edit

Whatever of several vaccines to foreclose Ebola

Ebola vaccine
Study Participant Receives NIAID-GSK Candidate Ebola Vaccine (3).jpg

Candidate Ebola vaccine beingness given
Vaccine description
Target Ebola virus
Vaccine type Viral vector
Clinical data
Trade names Ervebo, Zabdeno, Mvabea
ATC code
  • J07BX02 (WHO)
Legal status
Legal status
  • The states: ℞-only [i] [2]
  • European union: Rx-only [3] [4] [5]
Identifiers
CAS Number
  • 2581749-86-0

Ebola vaccines are vaccines either approved or in evolution to prevent Ebola. The offset vaccine to exist canonical in the Us was rVSV-ZEBOV in December 2019.[half-dozen] [7] It had been used extensively in the Kivu Ebola epidemic nether a empathetic employ protocol.[eight] During the early 21st century, several vaccine candidates displayed efficacy to protect nonhuman primates (normally macaques) against lethal infection.[nine] [ten] [xi]

Vaccines include replication-deficient adenovirus vectors, replication-competent vesicular stomatitis (VSV) and human parainfluenza (HPIV-iii) vectors, and virus-like nanoparticle preparations. Conventional trials to study efficacy past exposure of humans to the pathogen after immunization are not upstanding in this example. For such situations, the US Food and Drug Administration (FDA) has established the "fauna efficacy dominion" allowing licensure to be approved on the basis of animal model studies that replicate human disease, combined with evidence of safety and a potentially strong allowed response (antibodies in the claret) from humans given the vaccine. Clinical trials involve the administration of the vaccine to healthy human subjects to evaluate the immune response, place any side effects and make up one's mind the appropriate dosage.[12]

Approved [edit]

rVSV-ZEBOV [edit]

VSV-EBOV or rVSV-ZEBOV, sold under the brand proper name Ervebo, is a vaccine based on the vesicular stomatitis virus which was genetically modified to express a surface glycoprotein of Zaire Ebola virus.[13] [xiv] In November 2019, the European Commission granted a provisional marketing potency.[15] The WHO prequalification came fewer than 48 hours later on, making information technology the fastest vaccine prequalification process always conducted past WHO.[sixteen] It was canonical for medical utilize in the European Marriage in November 2019.[3] Information technology was approved for medical employ in the The states in Dec 2019.[6] [1]

The near common side furnishings include pain, swelling and redness at the injection site, headache, fever, muscle pain, tiredness and joint pain.[three] In general, these reactions occur within seven days after vaccination, are mild to moderate in intensity and resolved in less than a week.[3]

It was developed past the Public Wellness Agency of Canada, with development subsequently taken over by Merck Inc.[17] In October 2014, the Wellcome Trust, who was also one of the biggest Britain founders,[18] appear the first of multiple trials in healthy volunteers in Europe, Gabonese republic, Kenya, and the US.[nineteen] The vaccine was proven safety at multiple sites in North America, Europe, and Africa, but several volunteers at i trial site in Geneva, Switzerland, adult vaccine-related arthritis after about two weeks, and about 20–30% of volunteers at reporting sites adult low-grade mail service-vaccine fever, which resolved within a mean solar day or two. Other mutual side-effects were pain at the site of injection, myalgia, and fatigue.[20] The trial was temporarily halted in December 2014 due to possible adverse furnishings, but subsequently resumed.[21] Equally of April 2015[update], a Phase Three trial with a single dose of VSV-EBOV began in Liberia after a successful Phase 2 written report in the West African country.[22] On 31 July 2015, preliminary results of a Phase 3 trial in Guinea indicated that the vaccine appeared to be "highly efficacious and rubber."[23] The trial used a ring vaccination protocol that first vaccinated all the closest contacts of new cases of Ebola infection either immediately or after 21 days. Considering of the demonstrated efficacy of immediate vaccination, all recipients volition now be immunized immediately.[24] [25] Ring vaccination is the method used in the program to eradicate smallpox in the 1970s. The trial will proceed to assess whether the vaccine is effective in creating herd amnesty to Ebola virus infection.[26] In December 2016, a study plant the VSV-EBOV vaccine to be 95–100% effective against the Ebola virus, making information technology the kickoff proven vaccine confronting the disease.[27] [28] [29]

The approval was supported by a study conducted in Republic of guinea during the 2014–2016 outbreak in individuals 18 years of age and older.[six] The study was a randomized cluster (band) vaccination study in which 3,537 contacts, and contacts of contacts, of individuals with laboratory-confirmed Ebola virus disease (EVD) received either "firsthand" or 21-day "delayed" vaccination.[6] This blueprint was intended to capture a social network of individuals and locations that might include dwellings or workplaces where a patient spent time while symptomatic, or the households of individuals who had contact with the patient during that person's disease or death.[6] In a comparison of cases of EVD amongst ii,108 individuals in the "immediate" vaccination arm and ane,429 individuals in the "delayed" vaccination arm, Ervebo was determined to be 100% effective in preventing Ebola cases with symptom onset greater than x days subsequently vaccination.[6] No cases of EVD with symptom onset greater than ten days subsequently vaccination were observed in the "immediate" cluster group, compared with ten cases of EVD in the 21-solar day "delayed" cluster group.[6]

In boosted studies, antibody responses were assessed in 477 individuals in Liberia, some 500 individuals in Sierra Leone, and about 900 individuals in Canada, Spain, and the US.[half-dozen] The antibody responses among those in the report conducted in Canada, Spain and the U.s.a. were similar to those among individuals in the studies conducted in Liberia and Sierra Leone.[6]

The prophylactic was assessed in approximately fifteen,000 individuals in Africa, Europe, and North America.[6] The most usually reported side furnishings were pain, swelling and redness at the injection site, also as headache, fever, articulation and musculus aches and fatigue.[six]

In December 2016, a written report constitute the VSV-EBOV vaccine to be 70–100% effective against the Ebola virus, making it the first proven vaccine confronting the illness.[27] [28] [29] However, the design of this written report and the loftier efficacy of the vaccine were questioned.[30] In November 2019, the European Commission granted a conditional marketing authorisation to Ervebo (rVSV∆G-ZEBOV-GP, alive)[15] [31] [32] and the WHO prequalified an Ebola vaccine for the outset time.[16]

Zabdeno/Mvabea [edit]

The ii-dose regimen of Ad26.ZEBOV and MVA-BN-Filo, sold under the brand names Zabdeno and Mvabea,[4] [5] was developed by Johnson & Johnson at its Janssen Pharmaceutical visitor. It was approved for medical utilise in the European Wedlock in July 2020.[33] [four] [5]

The regimen consists of ii vaccine components (first vaccine as prime, followed by a second vaccine as boost)[34] - the first based on AdVac applied science from Crucell Kingdom of the netherlands B.V. (which is part of Janssen), the second based on the MVA-BN engineering from Bavarian Nordic. The Ad26.ZEBOV is derived from human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein, while the second component MVA-BN is the Modified Vaccinia Virus Ankara – Bavarian Nordic (MVA-BN) Filo-vector.[35] This product commenced Phase I clinical trial at the Jenner Institute in Oxford during January 2015.[36] [37] The preliminary data indicated the prime number-boost vaccine regimen elicited temporary immunologic response in the volunteers as expected from vaccination. The Stage II trial enrolled 612 developed volunteers and commenced in July 2015, in the United Kingdom and France. A 2nd Phase II trial, involving one,200 volunteers, was initiated in Africa[34] with the first trial commenced in Sierra Leone in October 2015.[38]

In September 2019, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted an accelerated cess to Janssen for Ad26.ZEBOV and MVA-BN-Filo,[39] and in November 2019, Janssen submitted a Marketing Dominance Application (MAA) to the EMA for approval of Ad26.ZEBOV and MVA-BN-Filo.[39] [40]

In May 2020, the EMA CHMP recommended granting a marketing authorization for the combination of Ad26.ZEBOV (Zabdeno) and MVA-BN-Filo (Mvabea) vaccines.[41] [42] [43] Zabdeno is given first and Mvabea is administered approximately eight weeks later as a booster.[41] This prophylactic two-dose regimen is therefore not suitable for an outbreak response where immediate protection is necessary.[41] As a precautionary measure out for individuals at imminent risk of exposure to Ebola virus (for example healthcare professionals and those living in or visiting areas with an ongoing Ebola virus illness outbreak), an extra Zabdeno booster vaccination should be considered for individuals who completed the Zabdeno-Mvabea 2-dose vaccination regimen more than than four months ago.[41] Efficacy for humans is non yet known as the efficacy has been extrapolated from animal studies.[44]

Ad5-EBOV [edit]

In late 2014 and early 2015, a double-blind, randomized Phase I trial was conducted in the Jiangsu Province of China; the trial examined a vaccine that contains glycoproteins of the 2014 strain, rather than those of the 1976 strain. The trial institute signals of efficacy and raised no significant safety concerns.[45]

In 2017, the China Food and Drug Administration (CFDA) announced blessing of an Ebola vaccine, co-developed by the Institute of Biotechnology of the Academy of Military Medical Sciences and the private vaccine-maker CanSino Biologics.[46] [47] Information technology contains a man adenovirus serotype v vector (Ad5) with the glycoprotein factor from ZEBOV.[48] Their findings were consistent with previous tests on rVSV-ZEBOV in Africa and Europe.[49]

In development [edit]

Vaccine Associated organisations Status
Chimp adenovirus 3 vectored glycoprotein (cAd3-EBO Z) GSK & NIAID Phase Three Feb. 2016[12]
rVSV vectored glycoprotein (VSV-EBOV) Newlink Genetics & Merck In use[fifty] [51] [15] [half-dozen]
Adenovirus 26 vectored glycoprotein / MVA-BN (Ad26.ZEBOV/​MVA-BN) Johnson & Johnson In use[35] [52]
HPIV-3 vectored glycoprotein Ministry building of Health (Russia) Phase I planned[53]
Rabies vectored glycoprotein Thomas Jefferson University & NIAID Non-human being primate claiming complete[54]
Purified glycoprotein Protein Sciences NHP challenge initiated[55]
Ebola ∆VP30 H2O2 treated University of Wisconsin Non-man primate challenge consummate[56]

cAd3-EBO Z [edit]

In September 2014, two Phase I clinical trials began for the vaccine cAd3-EBO Z, which is based on an attenuated version of a chimpanzee adenovirus (cAd3) that has been genetically contradistinct and then that it is unable to replicate in humans.[57] The cAd3 vector has a DNA fragment insert that encodes the Ebola virus glycoprotein, which is expressed on the virion surface and is critical for attachment to host cells and catalysis of membrane fusion.[58] It was adult by NIAID in collaboration with Okairos, now a partitioning of GlaxoSmithKline. For the trial designated VRC 20, 20 volunteers were recruited by the NIAID in Bethesda, Maryland, while three dose-specific groups of 20 volunteers each were recruited for trial EBL01 by Academy of Oxford, UK. Initial results were released in Nov 2014; all 20 volunteers developed antibodies against Ebola and there were no pregnant concerns raised about rubber.[59] [lx] In December 2014, University of Oxford expanded the trial to include a booster vaccine based on MVA-BN, a strain of Modified vaccinia Ankara, developed past Bavarian Nordic, to investigate whether it tin can assist increase immune responses further.[61] [62] The trial which has enrolled a total of 60 volunteers volition come across 30 volunteers vaccinated with the booster vaccine. As of April 2015[update], Stage Iii trial with a single dose of cAd3-EBO Z begins in Sierra Leone subsequently a successful Phase 2 study in W Africa countries.[22] [63]

Ebola GP vaccine [edit]

Recombinant formation plasmids

At the 8th Vaccine and ISV Conference in Philadelphia on 27−28 Oct 2014, Novavax Inc. reported the development in a "few weeks" of a glycoprotein (GP) nanoparticle Ebola virus (EBOV GP) vaccine using their proprietary recombinant engineering science. A recombinant protein is a protein whose code is carried by recombinant DNA. The vaccine is based on the newly published genetic sequence[64] of the 2014 Guinea Ebola (Makona) strain that is responsible for the 2014 Ebola illness epidemic in W Africa. In animal studies, a useful immune response was induced and was establish to be enhanced x to a hundred-fold past the company's "Matrix-M" immunologic adjuvant. A study of the response of non-human being primate to the vaccine had been initiated. Equally of February 2015[update], Novavax had completed two primate studies on baboons and macaques and had initiated a Phase I clinical trial in Australia. The Lipid nanoparticle (LNP)-encapsulated siRNAs rapidly adapted to target the Makona outbreak strain of EBOV and are able to protect 100% of rhesus monkeys confronting lethal challenge when treatment was initiated at 3 days postal service-exposure while animals were viremic and clinically ill.[65] The top line Phase I human being trial results showed that the adjuvanted Ebola GP Vaccine was highly immunogenic at all dose levels.[ medical citation needed ]

Nasal vaccine [edit]

On 5 November 2014, the Houston Chronicle reported that a research squad at the University of Texas-Austin was developing a nasal spray Ebola vaccine, which the team had been working on for 7 years.[66] The team reported in 2014, that in the nonhuman primate studies information technology conducted, the vaccine had more than efficacy when delivered via nasal spray than by injection.[67] As of November 2014[update], farther evolution by the team appeared unlikely due to lack of funding.[66] [68]

Vaxart tablet [edit]

Vaxart Inc. is developing a vaccine engineering science in the form of a temperature-stable tablet which may offering advantages such as reduced cold concatenation requirement, and rapid and scalable manufacturing. In January 2015, Vaxart announced that it had secured funding to develop its Ebola vaccine to Phase I trial.[69]

Attenuated Ebola virus vaccine [edit]

A report published in Science during March 2015, demonstrated that vaccination with a weakened form of the Ebola virus provides some mensurate of protection to non-human primates. This report was conducted in accordance with a protocol approved by an Institutional Animal Care and Use Committee of the National Institutes of Health.[seventy] The new vaccine relies on a strain of Ebola called EBOVΔVP30, which is unable to replicate.[56]

GamEvac-Combi [edit]

A study published in Human Vaccines & Immunotherapeutics in March 2017, analyzing information from a clinical trial of the GamEvac-Combi vaccine in Russia, concluded said vaccine to be prophylactic and constructive and recommended proceeding to Stage Iii trials.[71]

Prospects [edit]

In September 2019, a study published in Prison cell Reports demonstrated the office of the Ebola virus VP35 protein in its immune evasion. A recombinant course of Ebola virus with a mutant VP35 protein (VP35m) was adult, and showed positive results in the activation of the RIG-I-like receptor signaling. Not-homo primates were challenged with unlike doses of VP35. This challenge resulted in the activation of the innate allowed system and the production of anti-EBOV antibodies. The primates were then back-challenged with the wild type Ebola virus and survived. This potentially creates a prospect for a hereafter vaccine evolution.[72]

Clinical trials in West Africa [edit]

In January 2015, Marie-Paule Kieny, the World Health Organization's (WHO) assistant managing director-general of health systems and innovation, announced that the vaccines cAd3-EBO Z and VSV-EBOV had demonstrated acceptable safety profiles during early testing and would soon progress to large-scale trials in Liberia, Sierra Leone, and Guinea. The trials would involve up to 27,000 people and incorporate 3 groups – members of the first two groups would receive the two candidate vaccines, while the third grouping will receive a placebo.[73] Both vaccines have since successfully completed the Phase ii studies. The large scale Phase iii studies have begun as of April 2015[update], in Republic of liberia and Sierra Leone,[22] [63] and in Republic of guinea in March 2016.[25]

In addition, a medical anthropologist at Université de Montréal, had been working in Guinea and raised further questions most safe in the ring trial later on spending time in April at one of the Ebola handling units where trial participants are taken if they become sick, the centre in Coyah, almost 50km from the capital of Conakry.[20]

The Russian Strange Ministry appear in 2016, the intention to comport field trials of two Russian vaccines involving 2000 people.[74] According to local media reports, the Guinean government authorized the commencement of the trials on nine August 2017, at the Rusal-congenital Enquiry and Diagnostic Middle of Epidemiology and Microbiology in Kindia. The trials were slated to continue until 2018.[74] [75] As of October 2019, Russian federation licensed the vaccine by local regulatory authorities and was reportedly gear up to ship vaccine to Africa.[76]

U.South. national stockpile [edit]

In 2014, Credit Suisse estimated that the U.Due south. authorities will provide over $1billion in contracts to companies to develop medicine and vaccines for Ebola virus disease.[77] Congress passed a law in 2004 that funds a national stockpile of vaccines and medicine for possible outbreaks of illness.[77] A number of companies were expected to develop Ebola vaccines: GlaxoSmithKline, NewLink Genetics, Johnson & Johnson, and Bavarian Nordic.[77] Another visitor, Emergent BioSolutions, was a contestant for manufacturing new doses of ZMapp,[ commendation needed ] a drug for Ebola virus affliction treatment originally adult by Mapp Biopharmaceutical.[78] Supplies of ZMapp ran out in August 2014.[79] In September 2014, the Biomedical Avant-garde Research and Development Authority (BARDA) entered into a multimillion-dollar contract with Mapp Biopharmaceutical to accelerate the development of ZMapp.[80] Boosted contracts were signed in 2017.[81]

Run across likewise [edit]

  • Ebola virus disease
  • Ebola virus disease handling research

References [edit]

  1. ^ a b "Ervebo". U.S. Food and Drug Administration (FDA). xix December 2019. Retrieved one July 2020.
  2. ^ "Label of ERVEBO® (Ebola Zaire Vaccine, Live) Suspension for intramuscular injection Initial U.Southward. Approval: 2019". FDA. 2019. Retrieved 7 December 2021.
  3. ^ a b c d "Ervebo EPAR". European Medicines Agency (EMA). 12 Dec 2019. Retrieved 1 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is best-selling.
  4. ^ a b c "Zabdeno EPAR". European Medicines Agency (EMA). 26 May 2020. Retrieved 23 July 2020.
  5. ^ a b c "Mvabea EPAR". European Medicines Agency (EMA). 26 May 2020. Retrieved 23 July 2020.
  6. ^ a b c d e f g h i j k l "Starting time FDA-approved vaccine for the prevention of Ebola virus illness, marking a disquisitional milestone in public wellness preparedness and response". U.S. Nutrient and Drug Administration (FDA). 19 Dec 2019. Archived from the original on 20 December 2019. Retrieved xix December 2019. Public Domain This commodity incorporates text from this source, which is in the public domain .
  7. ^ McKee S (23 December 2019). "US approves Merck's Ebola vaccine". PharmaTimes Online. Surrey, England: PharmaTimes Media Limited. Retrieved 24 December 2019.
  8. ^ Beth Mole (16 April 2019). "Equally Ebola outbreak rages, vaccine is 97.5% effective, protecting over 90K people". Ars Technica.
  9. ^ Hoenen T, Groseth A, Feldmann H (July 2012). "Electric current ebola vaccines". Expert Opinion on Biological Therapy. 12 (seven): 859–72. doi:10.1517/14712598.2012.685152. PMC3422127. PMID 22559078.
  10. ^ Peterson AT, Bauer JT, Mills JN (January 2004). "Ecologic and geographic distribution of filovirus illness". Emerging Infectious Diseases. ten (1): 40–47. doi:10.3201/eid1001.030125. PMC3322747. PMID 15078595.
  11. ^ Fausther-Bovendo H, Mulangu S, Sullivan NJ (June 2012). "Ebolavirus vaccines for humans and apes". Electric current Opinion in Virology. 2 (3): 324–29. doi:x.1016/j.coviro.2012.04.003. PMC3397659. PMID 22560007.
  12. ^ a b Pavot Five (December 2016). "Ebola virus vaccines: Where practice we stand?". Clinical Immunology. 173: 44–49. doi:ten.1016/j.clim.2016.10.016. PMID 27910805.
  13. ^ Marzi A, Hanley Pw, Haddock Eastward, Martellaro C, Kobinger G, Feldmann H (October 2016). "Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona". The Periodical of Infectious Diseases. 214 (suppl 3): S360–66. doi:ten.1093/infdis/jiw218. PMC5050468. PMID 27496978.
  14. ^ Marzi A, Robertson SJ, Haddock E, Feldmann F, Hanley PW, Scott DP, et al. (August 2015). "Ebola Vaccine. VSV-EBOV quickly protects macaques against infection with the 2014/15 Ebola virus outbreak strain". Science. 349 (6249): 739–42. doi:10.1126/science.aab3920. PMID 26249231.
  15. ^ a b c "Merck's Ervebo [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Spousal relationship" (Press release). Merck. xi November 2019. Archived from the original on eleven Nov 2019. Retrieved 11 November 2019 – via Business concern Wire.
  16. ^ a b "WHO prequalifies Ebola vaccine, paving the way for its use in high-hazard countries" (Press release). World Wellness Organization. 12 November 2019. Archived from the original on 15 November 2019. Retrieved xiii November 2019.
  17. ^ "Canadian Ebola vaccine development taken over by Merck". CBC News. 24 November 2014. Retrieved 25 November 2014.
  18. ^ Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, et al. (August 2015). "Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial". Lancet. 386 (9996): 857–66. doi:10.1016/s0140-6736(15)61117-v. hdl:10144/575218. PMID 26248676. S2CID 40830730.
  19. ^ "Multiple trials of VSV Ebola vaccine accelerated by international collaborative" (Press release). Wellcome Trust. Retrieved 29 October 2014.
  20. ^ a b Shuchman M (May 2015). "Ebola vaccine trial in due west Africa faces criticism". Lancet. 385 (9981): 1933–34. doi:10.1016/s0140-6736(15)60938-2. PMID 25979835. S2CID 40400570.
  21. ^ Chan M. "WHO Director-General opens high-level meeting on Ebola vaccines". Globe Health System (WHO). Archived from the original on 18 January 2015. Retrieved 10 Jan 2015.
  22. ^ a b c "Ebola examination vaccines appear rubber in Phase 2 Liberian clinical trial" (Press release). National Institutes of Health (NIH). 26 March 2015.
  23. ^ Henao-Restrepo AM, Longini IM, Egger One thousand, Dean NE, Edmunds WJ, Camacho A, et al. (August 2015). "Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: acting results from the Guinea ring vaccination cluster-randomised trial". Lancet. 386 (9996): 857–66. doi:ten.1016/S0140-6736(xv)61117-five. hdl:10144/575218. PMID 26248676. S2CID 40830730.
  24. ^ "Ebola update (93): Positive vaccine trial results". ProMED mail. International Society for Infectious Diseases. Retrieved 2 August 2015.
  25. ^ a b "WHO analogous vaccination of contacts to contain Ebola flare-up in Republic of guinea". World Health Organisation (WHO). March 2016. Retrieved 14 May 2016.
  26. ^ "World on the verge of an effective Ebola vaccine" (Press release). World Health Organization (WHO). 31 July 2015. Archived from the original on 31 July 2015.
  27. ^ a b Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, et al. (February 2017). "Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: last results from the Republic of guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)". Lancet. 389 (10068): 505–eighteen. doi:10.1016/S0140-6736(16)32621-6. PMC5364328. PMID 28017403.
  28. ^ a b Berlinger J (22 December 2016). "Ebola vaccine gives 100% protection, report finds". CNN. Retrieved 27 Dec 2016.
  29. ^ a b "Last trial results ostend Ebola vaccine provides loftier protection against disease" (Press release). Globe Health Organization. 23 December 2016. Archived from the original on 11 Nov 2019. Retrieved 11 November 2019.
  30. ^ Metzger WG, Vivas-Martínez S (March 2018). "Questionable efficacy of the rVSV-ZEBOV Ebola vaccine". Lancet. 391 (10125): 1021. doi:10.1016/S0140-6736(18)30560-9. PMID 29565013.
  31. ^ "First vaccine to protect against Ebola". European Medicines Agency (Press release). 18 Oct 2019. Retrieved 15 October 2021.
  32. ^ "Ebola Zaire Vaccine (rVSV∆G-ZEBOV-GP, live)". Union Register of medicinal products . Retrieved 15 Oct 2021.
  33. ^ "Johnson & Johnson Announces European Commission Blessing for Janssen's Preventive Ebola Vaccine" (Press release). Johnson & Johnson. 1 July 2020. Retrieved sixteen July 2020 – via Reuters.
  34. ^ a b Bavarian Nordic (fifteen July 2015). "Bavarian Nordic announces that the Oxford Vaccines Group has initiated a Phase two study of the Ebola prime number-boost vaccine regimen combining MVA-BN Filo and Janssen's Advac engineering" (Press release). Copenhagen, Denmark: Bavarian Nordic. Retrieved 16 July 2015.
  35. ^ a b Clinical trial number NCT02313077 for "A Rubber and Immunogenicity Report of Heterologous Prime-Heave Ebola Vaccine Regimens in Salubrious Participants" at ClinicalTrials.gov
  36. ^ Walsh F (6 January 2015). "Ebola: New vaccine trial begins". BBC News Online. Retrieved six January 2015.
  37. ^ "Johnson & Johnson Announces Major Commitment to Speed Ebola Vaccine Evolution and Significantly Expand Production" (Printing release). Johnson & Johnson. Retrieved 6 January 2015.
  38. ^ Hirschler B (nine Oct 2015). "J&J starts vaccine trial in Sierra Leone, even every bit Ebola fades". Reuters. Retrieved fifteen October 2015.
  39. ^ a b "Johnson & Johnson Announces Submission of European Marketing Authorisation Applications for Janssen's Investigational Ebola Vaccine Regimen". Janssen. 17 November 2019. Archived from the original on 17 November 2019. Retrieved 16 Nov 2019.
  40. ^ Harper R (12 November 2019). "EU Marketing Authority submitted for Ebola vaccine regimen". European Pharmaceutical Review. Archived from the original on 17 November 2019. Retrieved 16 November 2019.
  41. ^ a b c d "New vaccine for prevention of Ebola virus disease recommended approval in the European Matrimony". European Medicines Agency (EMA) (Press release). 29 May 2020. Retrieved 29 May 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  42. ^ "Zabdeno: Pending EC decision". European Medicines Agency (EMA). 29 May 2020. Retrieved 29 May 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is best-selling.
  43. ^ "Mvabea: Pending EC decision". European Medicines Bureau (EMA). 29 May 2020. Retrieved 29 May 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is best-selling.
  44. ^ CZARSKA-THORLEY, Dagmara (29 May 2020). "New vaccine for prevention of Ebola virus disease recommended approval in the European Wedlock". European Medicines Bureau (EMA) . Retrieved 7 July 2020.
  45. ^ Zhu FC, Hou LH, Li JX, Wu SP, Liu P, Zhang GR, et al. (June 2015). "Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary written report of a randomised, double-blind, placebo-controlled, stage ane trial". Lancet. 385 (9984): 2272–79. doi:10.1016/S0140-6736(xv)60553-0. PMID 25817373. S2CID 34636122.
  46. ^ Feng C (xx October 2017). "China Approves Ebola Vaccine". Caixin Global. Archived from the original on seven October 2018. Retrieved 7 Oct 2018.
  47. ^ "Overview of candidate Ebola vaccines every bit of Baronial 19, 2019" (PDF). Strategic Informational Group of Experts. 19 Baronial 2019. Retrieved 7 December 2021.
  48. ^ Wong Chiliad, Mendoza EJ, Plummer FA, Gao GF, Kobinger GP, Qiu X (February 2018). "From bench to well-nigh bedside: the long road to a licensed Ebola virus vaccine". Skilful Stance on Biological Therapy. 18 (2): 159–73. doi:10.1080/14712598.2018.1404572. PMC5841470. PMID 29148858.
  49. ^ Hackett DW (31 March 2018). "Ebola Vaccine Development Race Between the United states and China". Precision Vaccinations.
  50. ^ "WHO coordinating vaccination of contacts to contain Ebola flare-up in Guinea". World Wellness Organization (WHO). Retrieved 20 July 2016.
  51. ^ "Vaccines alliance signs $5 meg advance deal for Merck's Ebola shot". Reuters. 20 January 2016. Retrieved twenty July 2016.
  52. ^ Milligan ID, Gibani MM, Sewell R, Clutterbuck EA, Campbell D, Plested E, et al. (Apr 2016). "Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial". JAMA. 315 (xv): 1610–23. doi:10.1001/jama.2016.4218. PMID 27092831.
  53. ^ "Ebola vaccines, therapies, and diagnostics". World Wellness Organisation (WHO). 6 July 2015. Archived from the original on 14 October 2014. Retrieved 10 September 2015.
  54. ^ Blaney JE, Marzi A, Willet 1000, Papaneri AB, Wirblich C, Feldmann F, et al. (thirty May 2015). "Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine". PLOS Pathogens. 9 (5): e1003389. doi:10.1371/journal.ppat.1003389. PMC3667758. PMID 23737747.
  55. ^ "CT lab hopes to stop spread of Ebola". three March 2015. Retrieved 10 September 2015.
  56. ^ a b Marzi A, Halfmann P, Hill-Batorski L, Feldmann F, Shupert WL, Neumann Thou, et al. (April 2015). "Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates". Science. 348 (6233): 439–42. doi:10.1126/science.aaa4919. PMC4565490. PMID 25814063.
  57. ^ Vaccine Enquiry Center, NIAID (ii October 2014). "Ebola Vaccine Clinical Development Overview (presentation)" (PDF). Earth Health Arrangement (WHO). Retrieved 21 October 2014.
  58. ^ Clinical trial number NCT02344407 for "Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)" at ClinicalTrials.gov
  59. ^ Ledgerwood JE, DeZure Advertisement, Stanley DA, Coates EE, Novik L, Enama ME, et al. (March 2017). "Chimpanzee Adenovirus Vector Ebola Vaccine". The New England Periodical of Medicine. 376 (10): 928–38. doi:10.1056/NEJMoa1410863. PMID 25426834.
  60. ^ Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, et al. (Oct 2014). "Chimpanzee adenovirus vaccine generates astute and durable protective immunity against ebolavirus challenge". Nature Medicine. 20 (10): 1126–29. doi:x.1038/nm.3702. PMID 25194571. S2CID 20712490.
  61. ^ Clinical trial number NCT02240875 for "A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN Filo" at ClinicalTrials.gov
  62. ^ University of Oxford (4 Dec 2014). "Booster Ebola vaccine enters showtime trials at Oxford Academy". Retrieved 7 December 2014.
  63. ^ a b "Ebola vaccine trial begins in Sierra Leone" (Printing release). Centers for Disease Control and Prevention (CDC). 14 April 2015.
  64. ^ Gire SK, Goba A, Andersen KG, Sealfon RS, Park DJ, Kanneh L, et al. (September 2014). "Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak". Science. 345 (6202): 1369–72. Bibcode:2014Sci...345.1369G. doi:10.1126/science.1259657. PMC4431643. PMID 25214632.
  65. ^ Thi EP, Mire CE, Lee Air conditioning, Geisbert JB, Zhou JZ, Agans KN, et al. (May 2015). "Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates". Nature. 521 (7552): 362–65. Bibcode:2015Natur.521..362T. doi:10.1038/nature14442. PMC4467030. PMID 25901685.
  66. ^ a b Ackerman T (five November 2014). "UT nasal spray vaccine for Ebola effective in monkeys". Houston Chronicle . Retrieved 13 November 2014.
  67. ^ Choi JH, Jonsson-Schmunk K, Qiu 10, Shedlock DJ, Strong J, Xu JX, et al. (August 2015). "A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection". Molecular Pharmaceutics. 12 (8): 2712–31. doi:10.1021/mp500646d. PMC4525323. PMID 25363619.
  68. ^ Stanton D (12 November 2014). "Ebola nasal vaccine under threat equally funding runs dry". in-PharmaTechnologist. Crawley, Sussex, Britain: William Reed Concern Media. Retrieved 13 November 2014.
  69. ^ "Vaxart Completes Financing to Fund Expanding Development Portfolio". Vaxart. Archived from the original on 19 January 2015. Retrieved 19 January 2015.
  70. ^ Marzi A, Feldmann F, Geisbert TW, Feldmann H, Safronetz D (Feb 2015). "Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses". Emerging Infectious Diseases. 21 (ii): 305–07. doi:10.3201/eid2102.141649. PMC4313664. PMID 25625358.
  71. ^ Dolzhikova Iv, Zubkova OV, Tukhvatulin AI, Dzharullaeva AS, Tukhvatulina NM, Shcheblyakov DV, et al. (March 2017). "Condom and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russian federation". Man Vaccines & Immunotherapeutics. 13 (3): 613–20. doi:10.1080/21645515.2016.1238535. PMC5360131. PMID 28152326.
  72. ^ Woolsey C, Menicucci AR, Cross RW, Luthra P, Agans KN, Borisevich V, et al. (September 2019). "A VP35 Mutant Ebola Virus Lacks Virulence simply Can Elicit Protective Immunity to Wild-Type Virus Challenge". Cell Reports. 28 (12): 3032–46.e6. doi:10.1016/j.celrep.2019.08.047. PMC6886687. PMID 31533029.
  73. ^ "UK leads promising Ebola vaccine trial Pharmaceutical company looking into largescale manufacturing if trials are successful". Ars Technica. 10 January 2015. Retrieved x January 2015.
  74. ^ a b "Russia to fund Ebola vaccine trials". Retrieved fourteen September 2017.
  75. ^ "Guinée: un vaccin trouvé et testé contre le virus Ebola – Afrique Sur seven : actualité de notre Afrique et du monde". www.afrique-sur7.fr (in French). Retrieved 14 September 2017.
  76. ^ "Russia gear up to supply Ebola vaccine to Africa". TASS . Retrieved 1 November 2019.
  77. ^ a b c Rooney B (28 October 2014). "Ebola: The making of a $1 billion drug". CNN . Retrieved 19 Nov 2014.
  78. ^ Gantz Southward (20 October 2014). "Emergent BioSolutions amongst three nether consideration for Ebola drug manufacturing". Baltimore Business Journal . Retrieved 13 Nov 2014.
  79. ^ Bernstein 50, Dennis B (11 August 2014). "Ebola examination drug's supply 'exhausted' afterward shipments to Africa, U.South. company says". The Washington Post . Retrieved 17 November 2019.
  80. ^ McCarthy Thou (September 2014). "US signs contract with ZMapp maker to accelerate development of the Ebola drug". BMJ. 349 (sep04 10): g5488. doi:10.1136/bmj.g5488. PMID 25189475.
  81. ^ "MappBio Announces Contracts with BARDA for ZMapp and Additional Filovirus Medical Countermeasures" (Press release). Mapp Biopharmaceutical. 29 September 2017. Archived from the original on 17 November 2019. Retrieved sixteen November 2019.

Farther reading [edit]

  • Choi MJ, Cossaboom CM, Whitesell AN, Dyal JW, Joyce A, Morgan RL, et al. (January 2021). "Use of Ebola Vaccine: Recommendations of the Advisory Commission on Immunization Practices, U.s.a., 2020" (PDF). MMWR Recomm Rep. 70 (one): i–12. doi:10.15585/mmwr.rr7001a1. PMC7802368. PMID 33417593.
  • Farooq F, Beck G, Paolino KM, Phillips R, Waters NC, Regules JA, Bergmann-Leitner ES (June 2016). "Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine". Scientific Reports. 6: 27944. Bibcode:2016NatSR...627944F. doi:x.1038/srep27944. PMC4914957. PMID 27323685.
  • Sullivan N, Yang ZY, Nabel GJ (September 2003). "Ebola virus pathogenesis: implications for vaccines and therapies". Journal of Virology. 77 (18): 9733–7. doi:x.1128/JVI.77.18.9733-9737.2003. PMC224575. PMID 12941881.
  • Diakite I, Mooring EQ, Velásquez GE, Murray MB (August 2016). "Novel Ordered Stepped-Wedge Cluster Trial Designs for Detecting Ebola Vaccine Efficacy Using a Spatially Structured Mathematical Model". PLOS Neglected Tropical Diseases. 10 (eight): e0004866. doi:10.1371/journal.pntd.0004866. PMC4979980. PMID 27509037.
  • Cazares LH, Ward Medico, Brueggemann EE, Kenny T, Demond P, Mahone CR, et al. (September 2016). "Development of a liquid chromatography high resolution mass spectrometry method for the quantitation of viral envelope glycoprotein in Ebola virus-like particle vaccine preparations". Clinical Proteomics. 13 (ane): 18. doi:10.1186/s12014-016-9119-eight. PMC5011338. PMID 27597813.
  • Konduru M, Shurtleff AC, Bradfute SB, Nakamura S, Bavari S, Kaplan Grand (September 2016). "Ebolavirus Glycoprotein Fc Fusion Protein Protects Republic of guinea Pigs against Lethal Challenge". PLOS One. 11 (9): e0162446. Bibcode:2016PLoSO..1162446K. doi:ten.1371/journal.pone.0162446. PMC5021345. PMID 27622456.
  • Cheng F, Murray JL, Zhao J, Sheng J, Zhao Z, Rubin DH (September 2016). "Systems Biological science-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap Insertional Mutagenesis". PLOS Computational Biology. 12 (ix): e1005074. Bibcode:2016PLSCB..12E5074C. doi:x.1371/periodical.pcbi.1005074. PMC5025164. PMID 27632082.
  • Olowookere SA, Abioye-Kuteyi EA, Adekanle O (November 2016). "Willingness to participate in Ebola viral affliction vaccine trials and receive vaccination by health workers in a tertiary hospital in Ile-Ife, Southwest Nigeria". Vaccine. 34 (47): 5758–5761. doi:10.1016/j.vaccine.2016.10.004. PMID 27751640.
  • Pavot V (December 2016). "Ebola virus vaccines: Where do we stand?". Clinical Immunology. 173: 44–49. doi:10.1016/j.clim.2016.x.016. PMID 27910805.
  • The Wellcome Trust–CIDRAP Ebola Vaccine Team B (January 2017). Completing the development of Ebola vaccines: electric current status, remaining challenges, and recommendations. Center for Infectious Disease Research and Policy (CIDRAP) and Wellcome Trust. Archived (PDF) from the original on 18 Jan 2017. Retrieved xviii January 2017.
  • Rosales-Mendoza Due south, Nieto-Gómez R, Angulo C (January 2017). "A Perspective on the Evolution of Plant-Made Vaccines in the Fight against Ebola Virus". Frontiers in Immunology. 8: 252. doi:ten.3389/fimmu.2017.00252. PMC5344899. PMID 28344580.

External links [edit]

  • "Ebola Vaccines". Drug Information Portal. U.S. National Library of Medicine.
  • Ebola Vaccines at the US National Library of Medicine Medical Subject Headings (MeSH)

looneyimen1962.blogspot.com

Source: https://en.wikipedia.org/wiki/Ebola_vaccine

0 Response to "Mexicans Who Invented the Vaccin Agains Ebola?"

Post a Comment

Subscribe to: Post Comments (Atom)

Iklan Atas Artikel

Iklan Tengah Artikel 1

Iklan Tengah Artikel 2

Iklan Bawah Artikel